MedTrace Logo

Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma

NCT04453397 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2021-09-23

No results posted yet for this study

Summary

This is a single patient protocol for TNB-383B in a subject with relapsed/refractory multiple myeloma (MM) who is not a candidate for treatment regimens known to provide clinical benefit in MM.

Conditions

Interventions

DRUG

TNB-383B

TNB-383B is a bispecific antibody targeting BCMA on tumor cells and CD3 on T-cells.

Sponsors & Collaborators

  • TeneoOne Inc.

    lead INDUSTRY

Principal Investigators

  • Ben Buelow · Amgen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04453397 on ClinicalTrials.gov